We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
The current CALA market cap is 487.25. The company's latest EPS is USD -4.3694 and P/E is 0.00.
| Year End 31 December 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 22.25M | 0 | 0 | 9.75M | 0 |
| Operating Income | -57.28M | -92.9M | -91.39M | -115.43M | -42.07M |
| Net Income | -54.63M | -89.86M | -90.14M | -115.09M | -21.29M |
| Year End 31 December 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 142.73M | 168.77M | 125.59M | 64.76M | 28.68M |
| Total Liabilities | 16.01M | 26.34M | 23.22M | 15.67M | 8.28M |
| Total Equity | 126.71M | 142.43M | 102.37M | 8.38M | 20.39M |
| Year End 31 December 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -64.84M | -78.75M | -84.31M | -66.3M | -43.61M |
| Investing | 52.8M | -10.78M | 88.96M | 7.85M | -133k |
| Financing | 14.63M | 98.91M | 42.06M | 10.67M | 9.66M |
| Market Cap | 487.25 |
| Price to Earnings Ratio | 0.00 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 0 |
| Price to Book Ratio | 0 |
| Dividend Yield | - |
| Shares Outstanding | 4.87M |
| Average Volume (1 week) | 593 |
| Average Volume (1 Month) | 625 |
| 52 Week Change | -99.68% |
| 52 Week High | 0.12 |
| 52 Week Low | 0.0001 |
| Spread (Intraday) | 0 (0%) |
| Company Name | Calithera Biosciences Inc (CE) |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.calithera.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
